Sign in
Create a Profile
Effects of Delta-9-THC and Iomazenil in Healthy Humans
Diseases and Conditions Researched
Mental Disorders; Psychotic Disorders; Schizophrenia
What is the purpose of this trial?
The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.
Participation Guidelines
Gender: Male
Click here for detailed participation information for this trial.
| Sponsor: | Yale University |
|---|---|
| Dates: | August 18, 2009 |
| Last Updated: | June 26, 2012 |
| Study HIC#: | 0901004662 |
| Clinicaltrials.gov ID: | NCT00982982 |
How will my information be used?
For more information about this trial, contact:
Brynn Huguenel, BA
203-932-5711
Ext. 4549
brynn.huguenel@yale.edu
Principal Investigator
Deepak C D'Souza, M.D
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
